Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7488707 | 0.84 | HTT (0.50) | SMN1; SMN2ALDH1A1KMT2AEPHX2KDM4E | |
| SCHEMBL5561161 | 0.79 | ALDH1A1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5561106 | 0.78 | ALDH1A1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4447989 | 0.77 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL8313950 | 0.76 | SSTR3 (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1357212 | 0.76 | ALDH1A1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL29336471 | 0.75 | HTT (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL923407 | 0.75 | MEN1 (0.64) | RAB9AALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL6076678 | 0.74 | ALDH1A1 (0.57) | NPC1RAB9AALDH1A1KMT2AHTT | |
| SCHEMBL18615761 | 0.74 | NAAA (0.54) | EPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329911-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-7642355-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(5-[4-(3-dimethylaminopropoxy)benzylamino]pentylcarbamoyl)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | NPC1 2695/4885RAB9A 1859/4885SMN1; SMN2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.